Is AEGR a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

594 people get AEGR articles and Market Currents by email alert.

Get email alerts on AEGR »

HEADLINES:

Insiders And Funds Are Bullish On These 3 Small Cap Healthcare Stocks
Kapitall • Tue, May 21
4 Companies With Extreme Price Charts And High Statistical Probability Of Decline
Richard Shaw • Fri, May 17 • 10 Comments
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (May 3, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference

GlobeNewswire (May 3, 2013)
Aegerion Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors

GlobeNewswire (Apr 29, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Needham Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Aegerion Pharmaceuticals to Announce First Quarter 2013 Financial Results on Tuesday, April 30

GlobeNewswire (Apr 16, 2013)
Insiders Are Buying These 4 Cash Rich Companies
Kapitall • Sun, Apr 7
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Apr 3, 2013)
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Fri, Mar 15
Aegerion Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 6
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results

GlobeNewswire (Mar 6, 2013)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Mar 5, 2013)
Aegerion Pharmaceuticals Observes Rare Disease Day

GlobeNewswire (Feb 28, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
Aegerion Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on Wednesday, March 6

GlobeNewswire (Feb 20, 2013)

To learn more about Seeking Alpha Pro, click here.

Aegerion Pharmaceuticals Expected To Take A Hit
WM Analyst • Sat, Feb 2 • 16 Comments
Aegerion: 2012 Was A Great Year But 2013 Could Be Better
C.R. Jackson • Thu, Jan 10 • 1 Comment
Aegerion's Lomitapide - FDA Approval, Strong Launch, Stock Price Increase Anticipated
LifeSci Advisors • Wed, Oct 24, 2012 • 24 Comments
Processing Aegerion Pharmaceuticals' Recent Rally
Brian L. Wilson • Thu, Oct 18, 2012
Aegerion, Should You Play It Safe And Ring The Bell?
Rx Stocks • Tue, Oct 16, 2012 • 5 Comments
Aegerion's Drug Lomitapide Should Receive FDA Approval
Beacon VP Investments • Fri, Oct 12, 2012 • 1 Comment
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis
LifeSci Advisors • Mon, Jul 2, 2012 • 11 Comments
Aegerion Pharmaceuticals: We Are Bullish On The Lomitapide Story
LifeSci Advisors • Fri, Jun 8, 2012 • 30 Comments
3 Reasons To Buy Aegerion Pharmaceuticals
Markus Aarnio • Mon, Jun 4, 2012 • 2 Comments

Insiders And Funds Are Bullish On These 3 Small Cap Healthcare Stocks
Kapitall • Tue, May 21
4 Companies With Extreme Price Charts And High Statistical Probability Of Decline
Richard Shaw • Fri, May 17 • 10 Comments
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Insiders Are Buying These 4 Cash Rich Companies
Kapitall • Sun, Apr 7
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Fri, Mar 15
VIX - Options Volatility And Market Sonar: Friday Recap
Erick McKitterick • Fri, Feb 15 • 4 Comments
JPMorgan Healthcare Conference 2013: Ultra-Orphan Drug And Health IT Companies Lead The Way
Raymond Chung • Wed, Feb 6 • 4 Comments
Isis Pharmaceuticals: A Compelling Long-Term Story
PropThink • Wed, Jan 30 • 6 Comments
Isis Pharmaceuticals: Kynamro's Approval Is An Antisense Home Run
Maani Value Guru • Wed, Jan 30 • 15 Comments
Isis Heats Up Ahead Of FDA Decision On Kynamro
Brian L. Wilson • Fri, Jan 11 • 4 Comments
Money Managers Are Buying These 3 Outperforming Drug Makers
Kapitall • Fri, Jan 4 • 2 Comments
Several Reasons Why I'm Considering These 2 Biotech Firms Before Year's End
Matt Schilling • Wed, Dec 26, 2012
Upcoming Orphan Drug Approval Decisions For 4 Biopharma Companies
LifeSci Advisors • Thu, Dec 20, 2012 • 2 Comments
Top 3 Stocks With Unusual Call Activities On Tuesday
Nick Chiu • Wed, Dec 19, 2012
Monday Options Brief: BAC, C & AEGR
Interactive Brokers • Mon, Dec 17, 2012
Upcoming Catalysts For 4 Biotech Stocks
LifeSci Advisors • Thu, Dec 6, 2012 • 8 Comments
2 Highly Liquid Biotech Stocks Positively Correlated To Volatility
Kapitall • Tue, Nov 20, 2012
Calendar Spreads Continue To Work Very Well And Pay Off
John Naccarelli • Wed, Oct 31, 2012
Sarepta Part I: The Possibility Of An Accelerated Approval Of Eteplirsen
LifeSci Advisors • Tue, Oct 23, 2012 • 20 Comments

Movers & Shakers: Thursday’s movers: Berkshire hit by S&P downgrade

at MarketWatch.com (Thu, 4:28PM)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (May 3, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference

GlobeNewswire (May 3, 2013)
Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors

GlobeNewswire (Apr 29, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Needham Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Aegerion Pharmaceuticals to Announce First Quarter 2013 Financial Results on Tuesday, April 30

GlobeNewswire (Apr 16, 2013)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Apr 3, 2013)
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results

GlobeNewswire (Mar 6, 2013)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Mar 5, 2013)
Aegerion Pharmaceuticals Observes Rare Disease Day

GlobeNewswire (Feb 28, 2013)
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
Aegerion Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on Wednesday, March 6

GlobeNewswire (Feb 20, 2013)
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences

GlobeNewswire (Feb 7, 2013)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Feb 7, 2013)
Aegerion Pharmaceuticals Prices Public Offering of Common Stock

GlobeNewswire (Jan 11, 2013)
Aegerion Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire (Jan 10, 2013)
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules

GlobeNewswire (Jan 7, 2013)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

GlobeNewswire (Jan 4, 2013)
Aegerion Pharmaceuticals Announces Presentation at the 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 3, 2013)

AEGR vs. ETF Alternatives

Company Description

Currently, there's no company description for AEGR.

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 3:14 PM Aegerion Pharmaceuticals (AEGR +32%) goes on a tear today, after CEO Marc Beer painted an upbeat picture for its rare-cholesterol-disease drug Juxtapid at a conference late yesterday. According to slides, Juxtapid will cost about $235K at initiation and will increase to $295K as of June 1st. Maintenance-stage costs will be around $295K, which will likely prompt the Street to adjust forecasts higher. View webcast here: (Aegerion Presentation) 5 Comments [Healthcare, On the Move]
Thursday, May 16, 12:51 PM Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%. 2 Comments [On the Move]
Tuesday, April 30, 9:37 AM Aegerion (AEGR): Q1 EPS of -$0.64 beats by $0.10. (PR) Comment! [Earnings, Breaking News]
Thursday, March 28, 11:54 AM Aegerion Pharmaceuticals (AEGR +6.5%) trades higher after Deutsche Bank reiterates Buy rating and raises price target to $52 from $41. DB says AEGR is on track to beat guidance of 250-300 patients using Juxtapid — its recently-approved treatment for a rare genetic disorder — by the end of the year. Comment! [Healthcare]
Wednesday, March 6, 7:16 AM Aegerion (AEGR): Q4 EPS of -$0.86 misses by $0.22. (PR) Comment! [Earnings, Breaking News]
Friday, January 11, 11:12 AM Aegerion Pharmaceuticals (AEGR +4.2%) bucks a weak tape after pricing its 2.7M share secondary offering at $26.24, flat with yesterday's close. The biopharmaceutical company said it expects net proceeds from the offering - which represents around 10% of its float - to be roughly $67.9M. Comment! [Healthcare, On the Move]
Thursday, January 10, 4:38 PM Aegerion Pharmaceuticals (AEGR) announces a secondary offering. All shares are being sold by Aegerion, and Jefferies and JPMorgan are acting as joint book-running managers. The sixe of the offering has not been disclosed, and is subject to market conditions. Shares +0.8% AH. Comment! [Healthcare]
Monday, December 24, 2012, 10:38 AM Aegerion Pharmaceuticals (AEGR -4.4%) is getting no love from investors this morning despite getting FDA approval for its first approved product, Juxtapid, a treatment for Hypercholesterolemia, which is an inherited disorder that can result in high cholesterol. However, the FDA is requiring a black box warning regarding the drug's liver toxicity, and the company also must certify doctors and receive preauthorization from insurers before patients can receive the drug. Comment! [Healthcare, On the Move]
Friday, October 19, 2012, 1:00 PM Isis Pharmaceutical (ISIS -3.6%) shares slip lower despite the FDA's announcement that it's recommended approval of Kynamro for the treatment of Hypercholesterolemia, as analysts dig deeper into the recommendation's details, which the FDA is not required to follow. Jefferies notes that the approval could be "very limited," while a Seeking Alpha report suggests that competitor Aegerion Pharma's (AEGR -5%) Lomitapide could be a better choice, with a more decisive vote from the committee and none of the safety concerns of Kynamro. 3 Comments [Healthcare, On the Move]
Thursday, October 18, 2012, 12:45 PM Midday top 10 gainers: CYBI +81%. OEH +26%. BWEN +23%. IESC +20%. ETH +20%. GIVN +18%. AEGR +17%. VIMC +16%. WCC +14%. CHCI +13.
Top 10 Losers: ALGN -24%. MNKD -23%. MLNX -21%. CYTR -19%. GORO -16%. IMUC -14%. RCON -13%. LXRX -11%. BCOM -11%. UFPI -11%. Comment! [On the Move]
Thursday, October 18, 2012, 9:10 AM Premarket gainers: GIVN +13%. WCC +11%. SVU +9%. JNPR +7%. NVAX +7%. MGM +6%. AEGR +5%.
Losers: MNKD -25%. CYTR -20%. ALGN -20%. IMUC -18%. LXRX -16%. MLNX -15%. GORO -14%. CDR -7%. SCSS -7%. VRNG -6%. 1 Comment [On the Move]
Thursday, October 18, 2012, 8:57 AM An FDA advisory panel votes 13-2 to recommend that the agency approve Aegerion's (AEGR +5%) lomitapide drug for treating very high cholestoral in patients with a rare genetic disease called homozygous familial hypercholesterolemia, which can lead to early death. The FDA is due to decide by the end of December. (PR) Comment! [Healthcare, On the Move]
Tuesday, October 16, 2012, 11:16 AM Aegerion (AEGR +6.6%) continues its uptrend, with the stock close to breaking out of a trading range that has persisted since 2011. The stock popped yesterday in reaction to an FDA staff report on its cholesterol drug lomitapide, and has ramped up nearly 35% since Friday in anticipation of its release. Comment! [Healthcare, On the Move]
Tuesday, October 16, 2012, 9:10 AM Premarket gainers: NOOF +54%. THLD +12%. MUR +8%. AEGR +7%. JOEZ +7%. CUR +7%. DPZ +6%.
Losers: RATE -26%. ISIS -20%. CLWR -19%. CMRE -10%. WAC -5%. GWW -5%. 1 Comment [On the Move]
Monday, October 15, 2012, 11:22 AM Aegerion Pharmaceuticals (AEGR +8.8%) trades up in reaction to a positive FDA staff report on its drug lomitapide. The drug treats a rare genetic disorder that causes very high cholesterol, and the report said that AEGR's plan to manage risk associated with it supports approval in adults with the most life-threatening forms. The drug is due to be reviewed on Wednesday by a committee of non-FDA medical experts, and the FDA will make a final decision by the end of December. 1 Comment [Healthcare, On the Move]
Monday, October 15, 2012, 9:10 AM Premarket gainers: YONG +15%. CLWR +14%. EDU +14%. AEGR +14%. CEL +9%. MTSL +8%. CTIC +8%. ISIS +7%.
Losers: DCTH -12%. 1 Comment [On the Move]

Kapitall
Insiders And Funds Are Bullish On These 3 Small Cap Healthcare Stocks $AEGR $INFI $PACB http://bit.ly/ZaYWvQ
1 hour ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (4/30/13): $AEGR, $ARE, $CHKP, $CPT, $CYNO, $ESS, $FOSL, $GK, $HOT, $HPY, $ITC, $MAR, $MJN, $OIS, $SAVE, $TGP
May 1, 10:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kapitall
Insiders are buying these 4 cash rich companies $AEGR $HNSN $JNS $TRGT http://seekingalpha.com/a/sesv
Apr 8, 7:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
My Swing Trading Watch-List for Long Setups | $LULU $KWK $AEGR $EW $ARRY and others. http://bit.ly/RCo0Zb
12/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/gDLl Premarket gainer $GIVN (12%), $NVAX(7%), $AEGR(6%)
10/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Hey Bull! It's been so good I've been thinking about taking some profits. You?
Apr 10, 8:00 PM
• !Report Abuse
Add a reply...

140 characters

ZetaKap
3 Analyst-Backed Pharmaceutical Stocks With Great Projections http://bit.ly/NTzNgg $AEGR $KERX $RIGL @ZetaKap
8/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 High Growth Pharmaceutical Stocks Holding Analysts' Confidence http://bit.ly/MEQjNU $AEGR $HZNP $KERX $PCRX $RIGL @ZetaKap
6/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Low-Debt Healthcare Stocks With Strong Analysts Ratings http://bit.ly/J1bs3p $ACHN $AFFY $ACAD $ABAX $AEGR $ACOR @ZetaKap
5/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
ZGNX, ELOS, SCMP, ABT, SPPI, MRK, AEGR, VRUS => Notable Developments and Results 11/30/10 => Rx Investors.com => http://bit.ly/c9Kc5C
11/30/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

freefdawatchlist
http://stks.co/gDLl Premarket gainer $GIVN (12%), $NVAX(7%), $AEGR(6%)
10/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Hey Bull! It's been so good I've been thinking about taking some profits. You?
Apr 10, 8:00 PM
• !Report Abuse
Add a reply...

140 characters

AEGR Aegerion Pharmaceuticals

AEGR

Aegerion Pharmaceuticals